Shares of Gilead fell after a key drug from the co
Post# of 26944
![](/assets/46931549/no_avatar_available_thumb.jpg)
The drugmaker said it will discuss the results with regulators and identify whether certain lung cancer patients may still benefit from the drug, called Trodelvy.
The results are a blow to Gilead, which is working to become a power player in the cancer space.
![Like This Post](/images/thumb-up.png)
![Dislike This Post](/images/thumb-down.png)